Search research articles
Contact Us
Filters
Showing results (1-10 of 260) with videos related to
Page
of 26
Sort By:
Blood
|
August 4, 2022
AML: making residual disease more measurable
Maria Teresa Voso, Francesco Buccisano
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Have we reached a molecular era in myelodysplastic syndromes?
Maria Teresa Voso, Carmelo Gurnari
Mediterranean Journal of Hematology and Infectious Diseases
|
May 26, 2022
De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences
Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso
Leukemia Research
|
November 24, 2012
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?
Massimo Breccia, Maria Teresa Voso, Giuliana Alimena
Expert Opinion on Pharmacotherapy
|
November 29, 2021
What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?
Carmelo Gurnari, Mariadomenica Divona, Maria Teresa Voso
Blood
|
April 20, 2021
What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms
Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani
Oncotarget
|
December 17, 2017
Progress and criticalities in the management of acute promyelocytic leukemia
Francesco Lo-Coco, Laura Cicconi, Maria Teresa Voso
Current Opinion in Oncology
|
September 10, 2015
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia
Maria Teresa Voso, Francesco Lo-Coco, Luana Fianchi
Haematologica
|
December 24, 2002
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
Giuseppe Leone, Luciana Teofili, Maria Teresa Voso, et al.
Clinical Immunology (Orlando, Fla.)
|
October 31, 2003
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
Giuseppe Leone, Maria Teresa Voso, Luciana Teofili, et al.
Page
of 26
Search research articles
Search
Showing results (1-10 of 260) with videos related to
Sort By:
Page
of 26
Blood
|
August 4, 2022
AML: making residual disease more measurable
Maria Teresa Voso, Francesco Buccisano
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Have we reached a molecular era in myelodysplastic syndromes?
Maria Teresa Voso, Carmelo Gurnari
Mediterranean Journal of Hematology and Infectious Diseases
|
May 26, 2022
De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences
Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso
Leukemia Research
|
November 24, 2012
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?
Massimo Breccia, Maria Teresa Voso, Giuliana Alimena
Expert Opinion on Pharmacotherapy
|
November 29, 2021
What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?
Carmelo Gurnari, Mariadomenica Divona, Maria Teresa Voso
Blood
|
April 20, 2021
What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms
Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani
Oncotarget
|
December 17, 2017
Progress and criticalities in the management of acute promyelocytic leukemia
Francesco Lo-Coco, Laura Cicconi, Maria Teresa Voso
Current Opinion in Oncology
|
September 10, 2015
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia
Maria Teresa Voso, Francesco Lo-Coco, Luana Fianchi
Haematologica
|
December 24, 2002
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
Giuseppe Leone, Luciana Teofili, Maria Teresa Voso, et al.
Clinical Immunology (Orlando, Fla.)
|
October 31, 2003
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
Giuseppe Leone, Maria Teresa Voso, Luciana Teofili, et al.
Page
of 26